A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MBX-102/JNJ-39659100 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Arhalofenate (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors CymaBay Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 12 Feb 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India, CTRI2009-091-000038).